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Abstract
Introduction—Before the introduction of the heptavalent pneumococcal conjugate vaccine
(Prevnar-7), the relative prevalence of serotypes of Streptococcus pneumoniae was fairly stable
worldwide. We sought to develop a statistical tool to predict the relative frequency of different
serotypes among disease isolates in the pre- and post-Prevnar-7 eras using the limited amount of
data that is widely available.
Methods—We initially used pre-Prevnar-7 carriage prevalence and estimates of invasiveness
derived from case-fatality data as predictors for the relative abundance of serotypes causing
invasive pneumococcal disease during the pre- and post-Prevnar-7 eras, using negative binomial
regression. We fit the model to pre-Prevnar-7 invasive pneumococcal disease data from England
and Wales and used these data to (1) evaluate the performance of the model using several datasets
and (2) evaluate the utility of the country-specific carriage data. We then fit an alternative model
that used polysaccharide structure, a correlate of prevalence that does not require country-specific
information and could be useful in determining the post-vaccine population structure, as a
predictor.
Results—Predictions from the initial model fit data from several pediatric populations in the pre-
Prevnar-7 era. Following the introduction of Prevnar-7, the model still had a good negative
predictive value, though substantial unexplained variation remained. The alternative model had a
good negative predictive value but poor positive predictive value. Both models demonstrate that
the pneumococcal population follows a somewhat predictable pattern even after vaccination.
Conclusions—This approach provides a preliminary framework to evaluate the potential
patterns and impact of serotypes causing invasive pneumococcal disease.
Invasive pneumococcal disease caused by Streptococcus pneumoniae (pneumococcus) is a
major cause of morbidity and mortality worldwide. There are at least 92 known serotypes,
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which differ in their nasopharyngeal carriage prevalence,1 their tendency to cause invasive
disease,2 and the severity of disease.3,4
Until 2000, when the heptavalent pneumococcal conjugate vaccine (Prevnar-7 or PCV7)
was introduced to the US childhood immunization program, the overall rank order of
serotypes causing invasive pneumococcal disease was similar in locales worldwide,
although the prevalence of specific serotypes varied over time, and some serotypes exhibited
distinct geographic patterns.5-7 Prevnar-7 targets seven clinically-important serotypes, and it
has successfully reduced the burden of pneumococcal disease in areas where it is widely
used.8,9 However, serotypes not covered by the vaccine have filled in the vacated niche,
leading to an increase in carriage of these other serotypes.10 Consequently, non-vaccine
serotypes have also increased in disease,8,9,11,12 although not enough to offset the benefits
of vaccination. Given the possibility that serotype replacement could reduce the overall
public health benefit of the vaccine, it is important to understand how the bacterial
population might change following vaccination.
We use regression models to evaluate which serotypes are most likely to increase in disease
following vaccination, and we discuss some potential applications of these approaches.
The incidence rate of invasive pneumococcal disease caused by a given serotype is the
product of the prevalence of nasopharyngeal carriage of that serotype and its invasiveness,13
defined here as the proportion of carriage episodes (or, more accurately, new acquisitions13)
that result in disease. An ideal model would use invasiveness and carriage prevalence data to
predict the disease incidence for each serotype. Because direct estimates of pediatric
invasiveness are unstable and available for a relatively small number of serotypes, we first
used a known correlate of invasiveness—adult case-fatality ratio (CFR)14,15—to generate
estimates of invasiveness for 37 serotypes. We combined the regression estimates of
invasiveness with carriage prevalence data from England to fit a model to invasive-disease
data from England and Wales, and evaluated its performance in various settings. This first
model effectively captured the observed serotype distribution in different locations, although
there remained substantial unexplained variation in the data. We next fit an alternative
model to the pre-vaccine disease data that used estimated invasiveness along with a correlate
of carriage prevalence—number of carbons per polysaccharide repeat unit.16 This second
model had a poor positive predictive value, but a good negative predictive value,
demonstrating that a single fixed biochemical determinant has an association with the
importance of a serotype in invasive disease. While there is still a large amount of
unexplained variation in the disease data, the models presented here demonstrate that the
distribution of pneumococcal serotypes follows a partially predictable pattern.
METHODS
Sources of data
Recent data on pediatric invasive pneumococcal disease cases (less than 5 years old) from
the pre- and post-Prevnar-7 eras were obtained from the Health Protection Agency of
England and Wales and the Active Bacterial Core surveillance system of the United States
Centers for Disease Control and Prevention (Table1).17 For the English data, we focused on
the epidemiologic year prior to the introduction of the vaccine (2005/2006) and the most
recent epidemiologic year from the post-vaccine era (2008/2009). With the US data, we
focused on the 2 years prior to the introduction of Prevnar-7 (1998-1999) and the most
recent three years from which data were available after vaccination (2005-2007). Data for
serotypes 6A and 6C were combined together and classified as “6A” for all analyses because
not all of the available studies distinguished between them. Pediatric carriage prevalence
data from a pre-vaccine English study18 was used to fit the model. We also sought to
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evaluate whether using country-specific carriage data would improve the predictions, so we
obtained data both on pediatric carriage and invasive disease of serotypes. We used pre-
vaccine carriage and disease data from Kenya (carriage data, Abdullahi et al19; disease data,
unpublished), and pre- and post- vaccine carriage data from Massachusetts.10,20 In the
carriage datasets from the US and from England and Wales, serotypes 15B and 15C were
not distinguished and are known to switch back and forth,21,22 so we divided the number of
15B/C cases equally between these two serotypes. All carriage prevalence data were natural-
log transformed, with serotypes not detected in carriage assigned a value of 0.5 prior to
transformation.
We obtained data on adult case-fatality ratio from a large Danish study of adult invasive
pneumococcal disease (Brueggemann et al,3 and unpublished data). The case-fatality ratio
was calculated for all serotypes that caused at least 20 cases of invasive pneumococcal
disease. Polysaccharide structural data (carbon/repeat unit) was obtained from published
reports as described previously.16 Missing polysaccharide structural data for serotypes 23A
and 35F were filled in using the mean values for other serotypes in their respective
serogroups.
Invasiveness estimates were obtained from Sleeman et al.13 and log-transformed prior to
use. These invasiveness estimates were considered only for serotypes that had at least 1
carriage and 1 disease isolate detected. Because invasiveness estimates were available for a
limited number of serotypes, we then performed linear regression using the case-fatality
ratio as a predictor of invasiveness. The results of the regression were then used to generate
estimates of invasiveness for all 37 serotypes that had case-fatality data, including serotypes
for which there was no direct estimate of invasiveness using the following formula:
The estimates generated by this regression were then used for all serotypes in downstream
analyses, regardless of whether direct estimates were available.
Prediction of the relative abundance of serotypes among invasive pneumococcal disease
isolates
Model 1—We first fit a log-linked negative binomial regression model to invasive
pneumococcal disease count data from England and Wales, using log-carriage prevalence
and log-estimated invasiveness as predictors. We considered only the 37 serotypes for which
we estimated invasiveness using case-fatality ratios. The resulting model was:
We also used the same model, with the same parameters calculated for England and Wales,
to predict serotype frequencies for the United States and Kenya, replacing English carriage
data with country-specific carriage data.
Model 2—We next fit an alternative model that used estimated invasiveness together with a
correlate of carriage prevalence—number of carbons per capsular polysaccharide repeat
unit. Again, we used log-linked negative binomial regression and fit the model to pediatric
invasive pneumococcal disease data from England and Wales, analyzing the 35 serotypes for
which we had data on both estimated invasiveness and polysaccharide structure. The
resulting model was:
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Evaluation of the fit of the models: We were primarily interested in the ability of Models 1
and 2 to predict relative contributions of serotypes to invasive disease. Spearman rank
correlations were used to assess the relationship between the predicted number of invasive
pneumococcal disease cases and the observed. Confidence intervals (CIs) for the correlation
coefficients were determined using Fisher’s transformation using the ci2 module in Stata. To
further evaluate the ability of the model to predict the relative contribution of serotypes, we
calculated the proportion of invasive pneumococcal disease caused by each serotype in a
given population, and then generated curves that represented the cumulative proportion of
invasive pneumococcal disease for each serotype based on the rank order predicted by the
models. Predicted curves with a larger area under the curve (closer to the observed line)
represented more accurate predictions.
All statistical analyses were performed using Intercooled Stata, version 9.2 (StataCorp,
College Station, TX.).
RESULTS
Estimation of pediatric invasiveness using case-fatality ratio
To obtain estimates of pediatric invasiveness for a large number of serotypes, we first
performed linear regression between pediatric invasiveness and adult case-fatality ratio. As
reported elsewhere,23 we found a moderate association between these two variables for the
20 serotypes for which we had data (linear regression, r2 = 0.58; eFigure 1,
http://links.lww.com). We then used the regression coefficients to estimate invasiveness for
all 37 serotypes for which we had case-fatality ratio data from a large Danish study. 24 (The
estimates for invasiveness are given in eTable 1, http://links.lww.com). Importantly, our
estimates of invasiveness obtained with this method performed as well or better than the
observed invasiveness measures in the downstream models (data not shown).
Model 1 results for England and Wales pre-vaccination
We next evaluated the ability of carriage prevalence and estimated invasiveness to predict
the relative contribution of serotypes to invasive pneumococcal disease among children
under the age of 5 years in England and Wales during the pre-Prevnar-7 era (2005-06). Not
surprisingly, serotypes with high carriage prevalence and high estimated invasiveness tended
to be more common among invasive pneumococcal disease isolates. The coefficients near 1
indicate that the regression recovered the multiplicative relationship between prevalence,
invasiveness, and invasive pneumococcal disease incidence. There was a strong correlation
between the observed and expected values (Table 2, Figure 1A, Spearman’s ρ = 0.82, (95%
confidence interval [CI] = 0.68-0.91)). Additionally, the cumulative proportion curve
generated using the predicted serotype ranks closely mirrors the observed cumulative
proportion curve (Figure 1B). The predicted values generated from univariate regressions
were not as strongly associated with the observed values as were the predicted values from
the multivariate regression (carriage prevalence alone (ρ = 0.66) or estimated invasiveness
alone (ρ = 0.24)).
Prediction of serotype ranks in different regions pre- and post-vaccination
We evaluated whether our predictions fit the serotype distributions in different regions in the
pre-Prevnar-7 era. We compared the predicted values obtained from the English data against
the observed serotype distributions from Kenya and the US. Reflecting the similar serotype
Weinberger et al. Page 4
Epidemiology. Author manuscript; available in PMC 2012 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
rank orders worldwide, we again found a strong association between the predicted values
from the model and the observed number of cases (Table 2).
Because serotype patterns in carriage are similar but not identical among regions, we sought
to improve the predictions by calculating the expected invasive pneumococcal disease
serotype frequencies using carriage prevalence data from the respective countries. The use
of country-specific carriage prevalence data led to a stronger correlation between the
observed and expected serotype frequencies in Kenya, but it did not substantially improve
the correlation for the US data (Table 2). The predictions made with the US carriage data,
however, did fit the US disease data better than the disease data from England and Wales or
Kenya.
Next we asked whether these models would have predicted the distribution of serotypes
causing invasive pneumococcal disease following the introduction of Prevnar-7. We
compared the predicted frequencies calculated from the model using carriage data from
England and Wales with the post-vaccine serotype ranks from England and Wales and the
US (Table 3, Figures 2A and 2C; non-vaccine serotypes only). There was a reasonably
strong association between the predicted and observed serotype ranks, although it was
weaker than for the pre-vaccine data. The model had a strong negative predictive value but
poor positive predictive value: This is evident when looking at the predicted cumulative
proportion curves (Figures 2B and 2D); some of the serotypes predicted to be common
contributed little to the cumulative proportion (on the left side of the graph), while the
serotypes the serotypes that were predicted to be rare (right side of the graph) were in fact
rare.
Unlike in the pre-Prevnar-7 era, the pre-Prevnar-7 carriage data from Massachusetts did not
improve the predictions for the US invasive pneumococcal disease data (Table 3). Serotypes
22F, 19A and 7F, which are among the most important serotypes in the post-vaccine era,
were predicted to be ranked 7th, 8th, and 9th out of 30 serotypes. Ranked above these
serotypes were types 6A/C, which might cross-react with anti-type 6B antibodies induced by
Prevnar-7, and types 1 and 8, which have been shown to exhibit regional variation and
temporal fluctuations.6,7 Also, serotypes 15C, 33F and 38 were predicted to be ranked
higher than 7F, 19A and 22F.
Model 2: Use of polysaccharide structure rather than prevalence as a predictor
We next made an alternative model that uses a recently-identified correlate of pre-and post-
vaccine carriage prevalence—number of carbons per capsular polysaccharide repeat
unit16—along with our estimates of invasiveness. In the regression model, polysaccharide
structure (number of carbons per polysaccharide repeat) was negatively associated with
serotype frequency in disease, while estimated invasiveness was positively correlated with
serotype frequency in the pediatric population in England and Wales. The expected values
generated from this model were correlated with the observed pre-Prevnar-7 serotype ranks
from England and Wales, the US, and Kenya (Table 4). When plotting the cumulative-
proportion curves based on the predicted serotype ranks, this model again had a strong
negative predictive value (right side of the graph) but relatively poor positive predictive
value (left side of the graph) (Figures 3A and 3B). In particular, the model predicted that
several serotypes (such as 3 and 9A) would be common that were, in fact, rare among
disease isolates. Additionally, serotype 1 was predicted to be the most common serotype;
while type 1 is common in England and Wales, it is relatively rare in the US. Comparing the
predicted serotype frequencies from Model 1 and Model 2 (eTable 2, http://links.lww.com),
there is good agreement between the two models for most serotypes. However, Model 2
predicts that types 1, 2, 3, 4, 5, 8, 9A, and 19A will be more common than predicted by
Model 1, while Model 1 predicts that serotype 6B would be more common than predicted by
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Model 2. In large part, this reflects the fact that polysaccharide structure is a good correlate
of carriage prevalence among circulating strains, but this structure does not predict whether
a particular serotype will be present in a given population.
Finally, we compared the predictions from this model to the observed serotype ranks in the
post-Prevnar-7 era among non-vaccine serotypes. As with the pre-Prevnar-7 population, the
model had a good negative predictive value but a poor positive predictive value (Table 4,
Figures 3C 3D). Similar to the results from the carriage-prevalence-based model, we could
not predict the exact post-Prevnar-7 rank order of serotypes, but the important replacing
serotypes (including 7F and 19A) were all ranked in the top half. Additionally, we found
that the predictions fit the post-PCV7 England and Wales data substantially better than the
post-PCV7 US data. This could be attributed, in part, to serotypes 1 and 8, which are
predicted by the model to be common but are rare in the US compared with England and
Wales.
DISCUSSION
Before the introduction of Prevnar-7, the rank order of serotypes causing invasive
pneumococcal disease was relatively stable worldwide and over time, but the pneumococcal
population has changed considerably now that conjugate vaccines are in widespread use.
Serotypes that were less common before the introduction of Prevnar-7 have now increased
in carriage frequency and have crept up among invasive pneumococcal disease isolates. It is
not yet clear, however, whether disease caused by replacement serotypes will constitute a
major concern in the future. In this study, we evaluated whether we could predict the rank
order of serotypes among disease isolates before and after the introduction of Prevnar-7
using carriage prevalence data (or a correlate of carriage prevalence) together with estimates
of invasiveness. The predictions fit the data from the pre-Prevnar-7 era, and in the post-
Prevnar-7 era, the predictions had a good negative but poor positive predictive value.
One potential application of this approach would be to use the estimated invasiveness data to
predict how different combinations of serotypes in carriage would affect disease burden. To
do this, we used the pre- and post-vaccine carriage data from Massachusetts (2001 vs 2007).
The data from these time periods were scaled so that the total numbers of carriage isolates in
the two populations were equal, and we used these data in model 1 to predict the disease
incidence for each serotype. We predicted that pneumococcal disease in children in the
United States would have declined by 28% based solely on differences in invasiveness of
the colonizing serotypes. We get similar estimates when we repeat this procedure with the
post-vaccine Massachusetts carriage data together20 with scaled pre-vaccine carriage data
from Norway25 (35% predicted reduction18) or with two English carriage studies (28%
predicted reduction or 30% predicted reduction using carriage data26). These estimates in
the reduction of pneumococcal disease are smaller than the 60% reduction in disease among
hospitalized cases in the United States,9 but are consistent with the 40% reduction in the
incidence of pneumococcal disease in children in England and Wales.27 These preliminary
findings demonstrate how carriage data, either from population-based studies or vaccine
trials, might be used to predict changes in disease burden.
A new 13-valent conjugate vaccine that targets the current Prevnar-7 serotypes as well as
serotypes 1, 3, 5, 6A, 7F, and 19A has been licensed in North America and Europe. If
effective, this vaccine, PCV13, will eliminate the most common causes of disease and will
provide another opportunity to study serotype replacement and to evaluate the predictions of
our model. While the incidence of different serotypes will be affected by numerous forces,
such as cross-reactivity between serotypes (e.g. anti-serotype 6B antibodies affecting
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serotype 6A), the model might help to capture some of the microbiological factors that will
influence the post-PCV13 bacterial population structure.
Our model does not account for all variation in the pneumococcal population structure, and
this likely reflects the fact that other host and bacterial factors can affect the serotype
distribution. Incorporating such factors into future models could improve the positive
predictive value of these models. Differences in immunogenicity between serotypes, the
immune status of the population, socioeconomic conditions, respiratory co-infections,
antibiotic use, and host population structure may all influence the observed patterns of
invasive pneumococcal disease incidence. Likewise, bacterial virulence factors other than
capsule could affect the ability of a serotype to emerge as a cause of invasive pneumococcal
disease. Serotype 1, for example, has a distinct geographic distribution of clones,28 and
recent work has started to explore noncapsular, genetic factors associated with
invasiveness.29,30 Additionally, some serotypes are known to exhibit long-term multi-year
fluctuations in incidence.7 The reasons for such fluctuation are not fully known but could
reflect shifts in the genetic background of the dominant serotypes. Because our approach
focuses only on the role of capsule—a major determinant of invasiveness—we are not able
to predict such fluctuations.
The results of our model further support the notion that the relative invasiveness of
serotypes is a fixed property.2 The model was initially fit using invasiveness and carriage
data from England, and we were able to substitute in carriage data from different locations
to improve the country-specific fit without changing the invasiveness values.
Following the introduction of Prevnar-7, the serotypes that increased in prevalence were the
most common non-vaccine serotypes before the vaccine. As a result, the pre-vaccine disease
data is a strong predictor of post-Prevnar-7 serotype ranks. However, while such an
approach might provide accurate estimates of post-Prevnar-7 serotype ranks in some
situation, it would probably not be effective at predicting the post-PCV13 population
structure because the vaccine will eliminate the majority of serotypes causing invasive
disease in an unvaccinated population. Our model has the advantage that, in the absence of
other information, we can make predictions about which of the remaining serotypes are
more or less likely to emerge.
In the pre-Prevnar-7 era, we found that the predicted values based on country-specific
carriage prevalence were more tightly correlated with invasive pneumococcal disease rank
for that country. However, in the post-Prevnar-7 era, the predicted values calculated with
England and Wales pre-Prevnar-7 carriage data were more tightly correlated with the US
invasive pneumococcal disease data than were the predicted values calculated with the
country-specific prevalence data. One possible reason is that fewer serotypes were detected
in the US carriage pre-Prevnar-7 studies than were detected in the England and Wales study.
As a result, it is impossible to distinguish between the rare serotypes and to predict which
are more likely to increase after vaccination. The pre-vaccine US carriage data were
collected during a single season in a single state, so it could be more likely to detect short-
term fluctuations in prevalence. Additionally, subjects in the Massachusetts carriage study
included only those who visited their pediatricians, and so the serotype distribution in this
population might be biased.
Previous work from our group16 suggests that there could be a biologic explanation for the
relative success of different serotypes in nasopharyngeal carriage. The microbial population
is not simply a random assemblage of serotypes but is influenced by microbial
characteristics that affect interactions with the host. Using the model with polysaccharide
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structure as a predictor, a single microbial factor, along with invasiveness, can be used to
predict the serotype rank order in several regions.
For the polysaccharide structure model, we found a good negative predictive value for the
model but poor positive predictive value. In particular, we would expect that serotypes such
as 1, 3, 5, and 9A would be among the most common serotypes in pediatric invasive
pneumococcal disease in the US, while in reality they were relatively rare. Types 1 and 5 are
common in some parts of the world and were formerly important in the United States, but
they are now rare in North America for unknown reasons.6,31,32 It has been suggested that
the difference in relative frequencies of these serotypes between regions is due to difference
in blood-culturing practices,33 although socioeconomic conditions, antibiotic use,
differences in the predominant clones, or other factors could also contribute.31,34
The models presented here demonstrate that the pneumococcal population structure follows
a somewhat predictable pattern, with the second model suggesting that this pattern is
influenced by stable microbiologic factors. These approaches also provide a framework for
evaluating how serotype composition in carriage could influence the disease burden in the
population. The approaches could be used to evaluate potential consequences of future
pneumococcal vaccines.
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Figure 1.
A, Comparison of predicted frequencies with observed serotype frequencies among pediatric
(age <5 years) invasive pneumococcal disease isolates during the pre-vaccine era in England
and Wales (2005-2006) (Spearman’s ρ = 0.82 [95% CI = 0.68-0.91]). B, Cumulative
proportion of disease explained by the expected rank order of serotypes (solid line with dots)
compared with the actual cumulative proportion curves (solid line) for England and Wales.
The dashed line represents the average cumulative proportion of disease explained by a
randomly permuted sample. The vertical jumps in the curves are the result of ties in rank.
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Figure 2.
A, Comparison of observed serotype frequencies among pediatric (age <5 years) invasive
pneumococcal disease isolates with predicted frequencies during the post-vaccine era in
England and Wales (2008-2009) (Spearman’s ρ = 0.75 [95% CI = 0.53-0.87]) and B, the
United States (2004-2007) (ρ = 0.55 [95%CI = 0.23-0.76]). C, Cumulative proportion of
disease explained by the expected rank order of serotypes (solid line with dots) compared
with the actual cumulative proportion curves (solid line) for England and Wales and D, the
US. The dashed line represents the average cumulative proportion of disease explained by a
randomly permuted sample. The vertical jumps in the curves are the result of ties in rank.
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Figure 3.
Use of polysaccharide structure, rather than carriage prevalence, to predict serotype ranks
pre- and post-Prevnar-7. Cumulative proportion of disease explained by the predicted rank
order of serotypes (solid line with dots) compared with the actual cumulative proportion
curves (solid line) for A, England and Wales, pre-Prevnar-7 and C, US, pre-Prevnar-7 or in
B, England and Wales, post-Prevnar-7 or D, the US, post-Prevnar-7. The vertical jumps in
the curves are the result of ties in rank.
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Table 3
Correlation of observed and predicted serotype ranks: after-Prevnar-7
Predicted (England and Wales) Predicted (USA/MA)
Observed (England and Wales 2008-2009) 0.75 (0.52-0.87) 0.51 (0.18-0.73)
Observed (USA 2005-2007) 0.55 (0.23-0.76) 0.25 (-0.12-0.56)
Comparison of observed serotype ranks with serotype ranks predicted by putting country-specific pre-Prevnar-7 carriage prevalence data into the
model. Non-vaccine serotypes only. Spearman’s rank correlation coefficients with 95% confidence intervals.
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Table 4
Model 2: Correlation of observed and predicted serotype ranks using polysaccharide structure as a predictor.
Pre-Prevnar-7
 England and Wales 2005-2006 0.59 (0.31-0.77)
 USA 1988-1999 0.59 (0.31-0.77)
 Kenya 0.72 (0.50-0.85)
Post-Prevnar-7
 England and Wales 2008-2009 0.44 (0.08-0.70)
 USA 2005-2007 0.12 (-0.27-0.47)
Comparison of observed serotype ranks with serotype ranks predicted by the model with polysaccharide structure and CRF. Spearman’s rank
correlation coefficients with 95% confidence intervals. In the post-vaccine era, only non-vaccine serotypes were included.
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